Related references
Note: Only part of the references are listed.Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours
T. R. Jeffry Evans et al.
BRITISH JOURNAL OF CANCER (2019)
Quantitative Analysis of Immune Infiltrates in Primary Melanoma
Robyn D. Gartrell et al.
CANCER IMMUNOLOGY RESEARCH (2018)
HLA-DR in Cytotoxic T Lymphocytes Predicts Breast Cancer Patients' Response to Neoadjuvant Chemotherapy
Diana P. Saraiva et al.
FRONTIERS IN IMMUNOLOGY (2018)
Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication
Samantha Burugu et al.
BREAST CANCER (2017)
Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer
Julienne L. Carstens et al.
NATURE COMMUNICATIONS (2017)
Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer
Ellen L. Goode et al.
JAMA ONCOLOGY (2017)
Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer
Shinichiro Kashiwagi et al.
PLOS ONE (2017)
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research
Shona Hendry et al.
ADVANCES IN ANATOMIC PATHOLOGY (2017)
Examining the common aetiology of serous ovarian cancers and basal-like breast cancers using double primaries
Colin B. Begg et al.
BRITISH JOURNAL OF CANCER (2017)
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
S. Loi et al.
ANNALS OF ONCOLOGY (2014)
Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states
T. Yoshida et al.
BRITISH JOURNAL OF CANCER (2014)
Multiplexed Quantitative Analysis of CD3, CD8, and CD20 Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
Jason R. Brown et al.
CLINICAL CANCER RESEARCH (2014)
Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
Sylvia Adams et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Multiplexed immunohistochemistry, imaging, and quantitation: A review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis
Edward C. Stack et al.
METHODS (2014)
Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer
Elena Garcia-Martinez et al.
BREAST CANCER RESEARCH (2014)
Characterization of the pharmacokinetics of a liposomal formulation of eribulin mesylate (E7389) in mice
Yanke Yu et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2013)
The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients
Catharina Medrek et al.
BMC CANCER (2012)
Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer A 2-Cohort, Phase 2 Study
Martee L. Hensley et al.
CANCER (2012)
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
Javier Cortes et al.
LANCET (2011)
Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
Carsten Denkert et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Cancer Metastasis Is Accelerated through Immunosuppression during Snail-induced EMT of Cancer Cells
Chie Kudo-Saito et al.
CANCER CELL (2009)
Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase
Tatiana Okouneva et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389
G Kuznetsov et al.
CANCER RESEARCH (2004)
Share Paper
